Pacific Edge Secures Singapore General Hospital Deal for Cxbladder Rollout

Pacific Edge Limited ( (PFGTF) ) has provided an update.

Pacific Edge has signed a service agreement enabling Singapore General Hospital, the country’s largest government-funded hospital, to order its Cxbladder Triage, Triage Plus, and Monitor tests for patients with hematuria and those under surveillance for bladder cancer recurrence. The move advances the company’s strategy to increase adoption of its non-invasive genomic urine tests in the Asia-Pacific region by leveraging Singapore General Hospital’s influence on clinical practice.

At Singapore General Hospital, Cxbladder will initially be used to offer microhematuria patients Triage Plus and lower-risk non-muscle invasive bladder cancer patients Monitor as alternatives to more frequent cystoscopies, with patients choosing between the invasive procedure and the test. Pacific Edge expects early testing volumes to be modest while clinicians become familiar with the platform, but believes the clinical and economic benefits demonstrated in international guidelines and real-world studies will support broader regional uptake and more efficient use of healthcare resources.

Triage Plus, a multi-modal RNA and DNA urine-based test, is positioned as the next-generation product with improved performance compared with the company’s earlier Triage and Detect tests for hematuria evaluation. Recently validated by the DRIVE study and building on randomized trial evidence that helped secure guideline inclusion for Cxbladder Triage, the new agreement underscores Pacific Edge’s ambition to cement its role in setting bladder cancer diagnostic standards across the Asia-Pacific market.

More about Pacific Edge Limited

Pacific Edge Limited is a global cancer diagnostics company specializing in the development and commercialization of bladder cancer diagnostic and prognostic tests for patients with hematuria and those under surveillance for recurrent disease. Headquartered in Dunedin, New Zealand, it delivers its Cxbladder suite of non-invasive genomic urine tests through CLIA-certified laboratories in New Zealand and the United States to customers across the U.S., Australasia, Israel, Asia, and South America.

Cxbladder tests are optimized for risk stratification of urothelial cancer in patients with microhematuria and in those monitored for recurrence, aiming to improve patient experience and clinical efficiency by reducing invasive procedures. Supported by more than two decades of research and over 25 peer-reviewed publications, Cxbladder Triage is incorporated into the American Urological Association’s Microhematuria Guideline and is widely used by thousands of urologists in the U.S., underpinning the platform’s growing clinical adoption worldwide.

For detailed information about PFGTF stock, go to TipRanks’ Stock Analysis page.